You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNitrendipine
Accession NumberDB01054  (APRD00421)
TypeSmall Molecule
GroupsApproved
DescriptionA calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
Structure
Thumb
Synonyms
1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
BAY e 5009
Bayotensin
Baypress
Bylotensin
Deiten
Nidrel
Nitrendipino
Nitrendipinum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BayotensinNot Available
BaypressNot Available
DeitenNot Available
NidrelNot Available
NitrepinNot Available
NitrezicNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9B627AW319
CAS number39562-70-4
WeightAverage: 360.3612
Monoisotopic: 360.132136382
Chemical FormulaC18H20N2O6
InChI KeyPVHUJELLJLJGLN-UHFFFAOYSA-N
InChI
InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
Pharmacology
IndicationFor the treatment of mild to moderate hypertension
Structured Indications Not Available
PharmacodynamicsNitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Mechanism of actionBy deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1CProteinyes
inhibitor
HumanQ13936 details
Voltage-dependent calcium channel subunit alpha-2/delta-1Proteinyes
inhibitor
HumanP54289 details
Voltage-dependent L-type calcium channel subunit beta-2Proteinyes
inhibitor
HumanQ08289 details
Voltage-dependent calcium channel gamma-1 subunitProteinyes
inhibitor
HumanQ06432 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinyes
inhibitor
HumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinyes
inhibitor
HumanQ13698 details
Voltage-dependent calcium channel subunit alpha-2/delta-2Proteinunknown
inhibitor
HumanQ9NY47 details
Voltage-dependent T-type calcium channel subunit alpha-1HProteinunknown
inhibitor
HumanO95180 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding> 99%
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nitrendipine Action PathwayDrug actionSMP00382
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nitrendipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nitrendipine.Vet Approved
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nitrendipine.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nitrendipine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Nitrendipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Nitrendipine.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nitrendipine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nitrendipine.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
AliskirenNitrendipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nitrendipine.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Nitrendipine.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nitrendipine.Approved, Investigational
AmifostineNitrendipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nitrendipine.Approved
AmiodaroneThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Nitrendipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Nitrendipine.Approved
AmobarbitalThe metabolism of Nitrendipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nitrendipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nitrendipine.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Nitrendipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nitrendipine.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nitrendipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nitrendipine.Approved
AprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrendipine.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nitrendipine.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.Approved
AtazanavirThe metabolism of Nitrendipine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Nitrendipine.Approved
AtomoxetineThe metabolism of Nitrendipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Atosiban.Approved
Atracurium besylateNitrendipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitrendipine.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nitrendipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Nitrendipine.Experimental
BarbitalThe metabolism of Nitrendipine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nitrendipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nitrendipine.Approved
BepridilNitrendipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Nitrendipine.Approved
BethanidineBethanidine may increase the hypotensive activities of Nitrendipine.Approved
BexaroteneThe serum concentration of Nitrendipine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nitrendipine.Approved
BimatoprostBimatoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Nitrendipine.Approved
BoceprevirThe metabolism of Nitrendipine can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Nitrendipine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Nitrendipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nitrendipine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine.Approved
BretyliumNitrendipine may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Nitrendipine.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nitrendipine.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Nitrendipine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Nitrendipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nitrendipine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine.Approved, Investigational
BupranololNitrendipine may increase the hypotensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nitrendipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nitrendipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nitrendipine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Nitrendipine.Approved
CalciumThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nitrendipine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.Approved
CandesartanCandesartan may increase the hypotensive activities of Nitrendipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nitrendipine.Withdrawn
CandoxatrilCandoxatril may increase the hypotensive activities of Nitrendipine.Experimental
CaptoprilNitrendipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine.Approved
CarbomycinThe metabolism of Nitrendipine can be decreased when combined with Carbomycin.Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nitrendipine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Nitrendipine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Nitrendipine.Approved
CarvedilolNitrendipine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine.Approved
CeliprololNitrendipine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Nitrendipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nitrendipine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nitrendipine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Nitrendipine.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nitrendipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nitrendipine.Approved, Investigational
CilazaprilNitrendipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine.Approved
CimetidineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nitrendipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nitrendipine.Approved
ClarithromycinThe metabolism of Nitrendipine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Nitrendipine can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nitrendipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nitrendipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Nitrendipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Nitrendipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nitrendipine.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Nitrendipine.Approved
CobicistatThe metabolism of Nitrendipine can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nitrendipine.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nitrendipine.Approved
ConivaptanThe serum concentration of Nitrendipine can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Nitrendipine.Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine.Investigational
CrizotinibThe metabolism of Nitrendipine can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nitrendipine.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Nitrendipine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Nitrendipine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.Approved
DabrafenibThe serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nitrendipine.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nitrendipine.Investigational
DarunavirThe metabolism of Nitrendipine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Nitrendipine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nitrendipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nitrendipine.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Nitrendipine.Experimental
DeferasiroxThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Nitrendipine can be decreased when combined with Delavirdine.Approved
DeserpidineNitrendipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine.Approved
DexamethasoneThe serum concentration of Nitrendipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nitrendipine.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nitrendipine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nitrendipine.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nitrendipine.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nitrendipine.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nitrendipine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nitrendipine.Approved
DihydralazineNitrendipine may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Nitrendipine can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Nitrendipine.Illicit
DiltiazemThe metabolism of Nitrendipine can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nitrendipine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Nitrendipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nitrendipine.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Nitrendipine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine.Approved, Investigational
DoxycyclineThe metabolism of Nitrendipine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Nitrendipine can be decreased when combined with Dronedarone.Approved
DuloxetineNitrendipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nitrendipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nitrendipine.Approved
EfavirenzThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nitrendipine.Approved
EfonidipineNitrendipine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nitrendipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrendipine.Approved
EnalaprilEnalapril may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
EnalaprilatNitrendipine may increase the hypotensive activities of Enalaprilat.Approved
EnzalutamideThe serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nitrendipine.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nitrendipine.Approved
EpoprostenolNitrendipine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanEprosartan may increase the hypotensive activities of Nitrendipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nitrendipine.Approved, Investigational
ErythromycinThe metabolism of Nitrendipine can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Nitrendipine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nitrendipine.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nitrendipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Nitrendipine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Nitrendipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nitrendipine.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nitrendipine.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nitrendipine.Approved
EtravirineThe serum concentration of Nitrendipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nitrendipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nitrendipine.Approved
FelodipineFelodipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Nitrendipine.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nitrendipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nitrendipine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nitrendipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine.Approved
FluconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nitrendipine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nitrendipine.Approved
FluvoxamineThe metabolism of Nitrendipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nitrendipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Nitrendipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nitrendipine.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nitrendipine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nitrendipine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Nitrendipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nitrendipine.Experimental
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nitrendipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nitrendipine.Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nitrendipine.Approved, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Nitrendipine.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Nitrendipine.Approved
GuanethidineNitrendipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Nitrendipine.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nitrendipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.Approved, Vet Approved
HexamethoniumNitrendipine may increase the hypotensive activities of Hexamethonium.Experimental
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nitrendipine.Approved
HexobarbitalThe metabolism of Nitrendipine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nitrendipine.Approved
HydralazineNitrendipine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nitrendipine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Nitrendipine.Approved
IdelalisibThe serum concentration of Nitrendipine can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
ImatinibThe metabolism of Nitrendipine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Nitrendipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nitrendipine.Approved
IndapamideIndapamide may increase the hypotensive activities of Nitrendipine.Approved
IndenololNitrendipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Nitrendipine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Nitrendipine.Approved, Investigational
IndoraminNitrendipine may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Nitrendipine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nitrendipine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
IsavuconazoniumThe metabolism of Nitrendipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitrendipine.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nitrendipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nitrendipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nitrendipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Nitrendipine.Approved, Withdrawn
IsradipineThe metabolism of Nitrendipine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Nitrendipine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nitrendipine.Approved, Vet Approved
JosamycinThe metabolism of Nitrendipine can be decreased when combined with Josamycin.Approved
KetanserinNitrendipine may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nitrendipine.Approved
KetoconazoleThe metabolism of Nitrendipine can be decreased when combined with Ketoconazole.Approved, Investigational
KitasamycinThe metabolism of Nitrendipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Nitrendipine.Approved
LacidipineNitrendipine may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nitrendipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nitrendipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nitrendipine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nitrendipine.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nitrendipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nitrendipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine.Approved
LevodopaNitrendipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nitrendipine.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nitrendipine.Approved
LisinoprilLisinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
LofexidineNitrendipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nitrendipine.Approved
LopinavirThe metabolism of Nitrendipine can be decreased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Nitrendipine.Approved
LovastatinThe metabolism of Nitrendipine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Nitrendipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Nitrendipine can be increased when combined with Lumacaftor.Approved
MacitentanNitrendipine may increase the hypotensive activities of Macitentan.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineNitrendipine may increase the hypotensive activities of Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Nitrendipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nitrendipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nitrendipine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nitrendipine.Approved
MethohexitalThe metabolism of Nitrendipine can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nitrendipine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nitrendipine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Nitrendipine.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nitrendipine.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitrendipine.Approved, Investigational
MethylphenobarbitalThe metabolism of Nitrendipine can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
MetipranololNitrendipine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneMetolazone may increase the hypotensive activities of Nitrendipine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nitrendipine.Approved, Investigational
MetyrosineNitrendipine may increase the hypotensive activities of Metyrosine.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nitrendipine.Experimental
MibefradilNitrendipine may increase the hypotensive activities of Mibefradil.Withdrawn
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nitrendipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Nitrendipine.Approved, Illicit
MifepristoneThe serum concentration of Nitrendipine can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nitrendipine.Approved
MinaprineMinaprine may increase the hypotensive activities of Nitrendipine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nitrendipine.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nitrendipine.Approved
MitotaneThe serum concentration of Nitrendipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nitrendipine.Approved, Investigational
MivacuriumNitrendipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nitrendipine.Approved
ModafinilThe serum concentration of Nitrendipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Nitrendipine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Nitrendipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nitrendipine.Vet Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Nitrendipine.Approved, Investigational
MoxonidineNitrendipine may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.Approved, Investigational
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nitrendipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Nitrendipine.Approved
NafcillinThe metabolism of Nitrendipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nitrendipine.Approved
NaftopidilNitrendipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nitrendipine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nitrendipine.Approved
NebivololNitrendipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Nitrendipine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Nitrendipine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Nitrendipine.Approved, Investigational
NetupitantThe serum concentration of Nitrendipine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Nitrendipine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nitrendipine.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Nitrendipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Nitrendipine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Nitrendipine.Approved
NiguldipineNitrendipine may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNitrendipine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineNimodipine may increase the hypotensive activities of Nitrendipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nitrendipine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nitrendipine.Approved, Investigational
NitroprussideNitrendipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nitrendipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine.Approved, Vet Approved
ObinutuzumabNitrendipine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nitrendipine.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Nitrendipine.Approved, Investigational
OlaparibThe metabolism of Nitrendipine can be decreased when combined with Olaparib.Approved
OleandomycinThe metabolism of Nitrendipine can be decreased when combined with Oleandomycin.Vet Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Nitrendipine.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nitrendipine.Approved
OsimertinibThe serum concentration of Nitrendipine can be increased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nitrendipine.Approved
OxprenololNitrendipine may increase the hypotensive activities of Oxprenolol.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nitrendipine.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Nitrendipine.Investigational
PalbociclibThe serum concentration of Nitrendipine can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nitrendipine.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nitrendipine.Approved
PargylinePargyline may increase the hypotensive activities of Nitrendipine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.Approved
PenbutololNitrendipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nitrendipine.Approved
PentobarbitalThe metabolism of Nitrendipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumNitrendipine may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitrendipine.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Nitrendipine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Nitrendipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhenobarbitalThe metabolism of Nitrendipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nitrendipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nitrendipine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PinacidilNitrendipine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPindolol may increase the hypotensive activities of Nitrendipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.Approved
PirlindolePirlindole may increase the hypotensive activities of Nitrendipine.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
PolythiazideNitrendipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nitrendipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nitrendipine.Approved
PosaconazoleThe metabolism of Nitrendipine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Nitrendipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PrimidoneThe metabolism of Nitrendipine can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Nitrendipine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Nitrendipine.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nitrendipine.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Nitrendipine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Nitrendipine.Approved
QuinineQuinine may increase the hypotensive activities of Nitrendipine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nitrendipine.Experimental
RamiprilRamipril may increase the hypotensive activities of Nitrendipine.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nitrendipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nitrendipine.Approved, Investigational
RapacuroniumNitrendipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nitrendipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Nitrendipine.Approved
RescinnamineNitrendipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Nitrendipine.Approved
RifabutinThe metabolism of Nitrendipine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Nitrendipine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Nitrendipine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nitrendipine.Approved, Investigational
RilmenidineNitrendipine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatNitrendipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNitrendipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Nitrendipine can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNitrendipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nitrendipine.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nitrendipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Nitrendipine.Withdrawn
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nitrendipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nitrendipine.Approved, Vet Approved
SaprisartanNitrendipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Nitrendipine can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Nitrendipine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nitrendipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nitrendipine.Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nitrendipine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nitrendipine.Approved
SiltuximabThe serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Nitrendipine can be increased when it is combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nitrendipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nitrendipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nitrendipine.Approved, Investigational
SitaxentanNitrendipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nitrendipine.Approved
SolithromycinThe metabolism of Nitrendipine can be decreased when combined with Solithromycin.Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nitrendipine.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitrendipine.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nitrendipine.Experimental
SpiraprilNitrendipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nitrendipine.Approved
St. John's WortThe serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Nitrendipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nitrendipine.Approved
SulfisoxazoleThe metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Nitrendipine.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nitrendipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nitrendipine.Experimental
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nitrendipine.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nitrendipine.Approved
TelaprevirThe metabolism of Nitrendipine can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Nitrendipine can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TemocaprilNitrendipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nitrendipine.Approved
TerazosinTerazosin may increase the hypotensive activities of Nitrendipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nitrendipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nitrendipine.Approved
TerlipressinNitrendipine may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Nitrendipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nitrendipine can be increased when combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nitrendipine.Approved
TiboloneNitrendipine may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nitrendipine.Approved
TiclopidineThe metabolism of Nitrendipine can be decreased when combined with Ticlopidine.Approved
TicrynafenNitrendipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Nitrendipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nitrendipine.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitrendipine.Approved
TocilizumabThe serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab.Approved
TolazolineTolazoline may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nitrendipine.Approved, Vet Approved
ToloxatoneToloxatone may increase the hypotensive activities of Nitrendipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nitrendipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Nitrendipine.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Nitrendipine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Nitrendipine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nitrendipine.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitrendipine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nitrendipine.Approved
TravoprostTravoprost may increase the hypotensive activities of Nitrendipine.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nitrendipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitrendipine.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nitrendipine.Approved, Vet Approved
TrimazosinNitrendipine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanNitrendipine may increase the hypotensive activities of Trimethaphan.Approved
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nitrendipine.Approved, Investigational
TroleandomycinThe metabolism of Nitrendipine can be decreased when combined with Troleandomycin.Approved
TylosinThe metabolism of Nitrendipine can be decreased when combined with Tylosin.Vet Approved
UdenafilUdenafil may increase the antihypertensive activities of Nitrendipine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nitrendipine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nitrendipine.Approved
UnoprostoneNitrendipine may increase the hypotensive activities of Unoprostone.Approved
Ursodeoxycholic acidUrsodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Nitrendipine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nitrendipine.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Nitrendipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Nitrendipine.Approved
VenlafaxineThe metabolism of Nitrendipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Nitrendipine can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nitrendipine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Nitrendipine.Approved, Investigational
VinpocetineNitrendipine may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nitrendipine.Approved
VoriconazoleThe metabolism of Nitrendipine can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineNitrendipine may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nitrendipine.Approved, Vet Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nitrendipine.Approved
ZiprasidoneThe metabolism of Nitrendipine can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, “Preparation of solid medicament formulation containing nitrendipine.” U.S. Patent US4724141, issued April, 1980.

US4724141
General ReferencesNot Available
External Links
ATC CodesC08CA08C09BB06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9536
Blood Brain Barrier-0.9549
Caco-2 permeable+0.7853
P-glycoprotein substrateSubstrate0.5265
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.8313
Renal organic cation transporterNon-inhibitor0.8984
CYP450 2C9 substrateNon-substrate0.8212
CYP450 2D6 substrateNon-substrate0.8931
CYP450 3A4 substrateSubstrate0.7266
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorInhibitor0.8037
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9247
Ames testNon AMES toxic0.7334
CarcinogenicityNon-carcinogens0.5186
BiodegradationNot ready biodegradable0.9581
Rat acute toxicity2.3810 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8131
hERG inhibition (predictor II)Non-inhibitor0.9094
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156-160 °CNot Available
water solubilityInsolubleNot Available
logP2.88MASUMATO,K ET AL. (1995)
Caco2 permeability-4.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0142 mg/mLALOGPS
logP3.21ALOGPS
logP2.17ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)5.43ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity96.91 m3·mol-1ChemAxon
Polarizability36.25 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Nitrobenzene
  • Dihydropyridinecarboxylic acid derivative
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxylic acid ester
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only as a multiple subunit complex.
Gene Name:
CACNG1
Uniprot ID:
Q06432
Molecular Weight:
25028.105 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  2. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23